EP3668859A1 — Solid forms of an hiv capsid inhibitor
Assigned to Gilead Sciences Inc · Expires 2020-06-24 · 6y expired
What this patent protects
The present invention relates to salts, pharmaceutically acceptable crystals and corresponding crystalline forms of a compound which is N - ((S ) -1- (3- (4-chloro-3- (methylsulfonamido) -1- , 2,2-trifluoroethyl) -LH-indazol-7-yl) -6- (3-methyl-3- (methylsulfonyl) but-1-yn-1-yl…
USPTO Abstract
The present invention relates to salts, pharmaceutically acceptable crystals and corresponding crystalline forms of a compound which is N - ((S ) -1- (3- (4-chloro-3- (methylsulfonamido) -1- , 2,2-trifluoroethyl) -LH-indazol-7-yl) -6- (3-methyl-3- (methylsulfonyl) but-1-yn-1-yl) pyridin-2-yl) -2- (3 , 5-difluorophenyl) ethyl) -2 - ((3BS, 4aR) -5,5-difluoro-3- (trifluoromethyl) -3b, 4,4a, 5-tetrahydro-1H-cyclopropa [3,4] cyclopenta [1 , 2-c] pyrazol-1-yl) acetamide, which is useful in the treatment of a viral infection with Retroviridae comprising an infection caused by the HIV virus.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.